- Patients diagnosed of active AS who will start anti-TNF therapy following standard
clinical practice as per summary of product characteristics doses.
- >18 years, both genders, any disease duration
- Signature of informed consent
- Previous treatment with biological therapies
- Active tuberculosis infection (local guidelines for appropriate screening and
treatment of tuberculosis in the setting of anti-TNF therapy must be followed)